Company Overview

Zealand Pharma A/S is a Danish biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines, primarily targeting metabolic diseases, obesity, rare diseases, and gastrointestinal disorders. The company operates within the global biopharmaceutical industry and concentrates on therapies that leverage peptide engineering and receptor biology to address chronic conditions with significant unmet medical need. Its revenue has historically been generated through licensing agreements, collaboration payments, milestone payments, and research partnerships, while it continues advancing wholly owned and partnered drug candidates through clinical development.

The company was founded in 1998 and is headquartered in Copenhagen, Denmark. Zealand Pharma evolved from an early-stage peptide research company into a clinical-stage biotechnology enterprise with multiple late-stage and mid-stage therapeutic programs. Its strategic positioning is tied to expertise in peptide therapeutics and long-acting formulations, particularly within obesity and metabolic disease treatment markets. The company has built collaborations with major pharmaceutical companies to support development, commercialization, and global market reach.

Business Operations

Zealand Pharma’s operations are centered around its peptide therapeutics platform and clinical development pipeline. Its core business activities include drug discovery, preclinical research, clinical development, and strategic licensing. Key development programs have included therapies targeting obesity, type 2 diabetes, congenital hyperinsulinism, short bowel syndrome, and inflammatory conditions. Important business and development assets include petrelintide, an amylin analog for obesity management, and dasiglucagon, a glucagon analog developed for severe hypoglycemia and related disorders. The company has also maintained partnerships involving dual and combination therapies aimed at metabolic disease treatment.

The company operates internationally through research collaborations, licensing agreements, and clinical trial activities across North America, Europe, and other regions. Zealand Pharma has entered partnerships with major pharmaceutical companies including Boehringer Ingelheim and previously collaborated with companies such as Sanofi and Alexion Pharmaceuticals on selected programs. Its operations rely heavily on proprietary peptide engineering technologies, intellectual property portfolios, and clinical-stage development capabilities rather than large-scale commercial manufacturing infrastructure.

Strategic Position & Investments

Zealand Pharma’s strategic direction emphasizes expansion in obesity and metabolic disease therapeutics, areas experiencing substantial global pharmaceutical investment and demand growth. The company has prioritized advancing differentiated peptide therapies that may offer improved tolerability, efficacy, or combination potential compared with existing incretin-based therapies. Its development strategy includes both wholly owned assets and co-development partnerships designed to reduce financial risk while preserving long-term commercialization opportunities.

Recent strategic initiatives have focused on advancing obesity pipeline candidates and broadening metabolic disease applications through combination therapies and next-generation peptide technologies. Investments have been directed toward clinical trials, manufacturing readiness, and global development capabilities. The company’s portfolio includes proprietary peptide candidates and collaborative programs spanning obesity, rare endocrine disorders, and gastrointestinal diseases. Zealand Pharma has also strengthened its capital position through public market financing activities and strategic alliances intended to support late-stage clinical development.

Geographic Footprint

Zealand Pharma is headquartered in Copenhagen, Denmark, and maintains a global operational footprint through clinical programs, partnerships, and investor activities. The company’s primary commercial and development focus areas include North America and Europe, which represent the largest pharmaceutical markets for obesity and metabolic disease therapies. Clinical trial operations and regulatory activities also extend into additional international jurisdictions depending on program requirements.

The company’s partnerships with multinational pharmaceutical firms have expanded its international influence beyond Denmark, particularly within the United States, where much of the global obesity and diabetes pharmaceutical market is concentrated. Zealand Pharma’s investor base and stock market presence include listings and trading activity connected to both European and U.S. capital markets, supporting broader international visibility and access to financing.

Leadership & Governance

Zealand Pharma is governed by a board of directors and executive leadership team with experience across biotechnology research, pharmaceutical development, and global commercialization. The company’s leadership strategy has emphasized scientific innovation, disciplined clinical development, and strategic partnerships to advance peptide-based therapeutics in high-growth disease categories. Corporate governance practices are aligned with Danish public company standards and applicable international market regulations.

Key executives include:

• Adam Steensberg – President and Chief Executive Officer
• Mats Blom – Chief Financial Officer
• David Kendall – Chief Medical Officer
• Mikael Dolsten – Chair of the Board of Directors
• Kenneth Galbraith – Member of the Board of Directors
• Martin Nicklasson – Member of the Board of Directors

The leadership team has consistently articulated a strategy centered on building a leading peptide therapeutics company with a strong presence in obesity and metabolic disease treatment markets, supported by scientific specialization and external partnerships.